Virios Therapeutics (Virios Therapeutics) Beta : 2.04 (As of May. 16, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-16), Virios Therapeutics's Beta is 2.04.

Virios Therapeutics Beta Historical Data

The historical data trend for Virios Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics Beta Chart

Virios Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

Get a 7-Day Free Trial

1.94

Virios Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beta	Get a 7-Day Free Trial															-	-	-	1.94	1.94

Competitive Comparison of Virios Therapeutics's Beta

For the Biotechnology subindustry, Virios Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virios Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's Beta falls into.

Virios Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Virios Therapeutics (NAS:VIRI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Virios Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009